ANDROGENREZEPTOR-ANTISENSE-OLIGONUKLEOTIDE

European patent · EP3497114 · In force

Register entry

Publication number
EP3497114
Application number
EP17838864
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 24, 2017
Published
Jun 19, 2019
Granted
Oct 16, 2024
Protection ends at the latest
May 23, 2037
Next annual fee due
May 31, 2026
IPC classes
C12N 15/113 (2010.01)
C12N 15/11 (2006.01)
Priority
US 201662372035 P 08.08.2016
PCT application
PCT/IB2017/000697 24.05.2017
PCT publication
WO2018/029517 15.02.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Dec 2, 2025

    Change

    Published in Swissreg on 02.12.2025

  2. Aug 27, 2025

    Change

    Published in Swissreg on 27.08.2025

  3. Dec 5, 2024

    Agent entered

    Representative
    HGF GmbH, OBC Suisse AG, Aeschengraben 29, 4051 Basel

    Published in Swissreg on 05.12.2024

  4. Oct 16, 2024

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 16.10.2024

Parties

Holder

Olipass Corporation

20th Floor Ace Dongbaek Tower 16 Beon-gil 16-4 Dongbaek Jungang-ro Giheung-gu, Yongin-si, Gyeonggi-do 17105, KR

Agent

HGF GmbH

OBC Suisse AG Aeschengraben 29, 4051 Basel

Inventor

CHUNG, Shin

Yongin-si Gyeonggi-do 16990, KR

JUNG, Daram

Hwaseong-si Gyeonggi-do, KR

CHO, Bongjun

Yongin-si Gyeonggi-do 17077, KR

JANG, Kangwon

Yongin-si Gyeonggi-do 16998, KR

YOON, Heungsik

Seongnam-si Gyeonggi-do 13623, KR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.